Showing posts with label Chronic Kidney Disease Market. Show all posts
Showing posts with label Chronic Kidney Disease Market. Show all posts

Monday, 10 June 2019

Chronic Kidney Disease Market Poised For Steady Growth In The Future To 2023

ResearchMoz presents professional and in-depth study of "Chronic Kidney Disease: Global Markets and Technologies Through 2023".

The study presents an outline of the global Chronic Kidney Disease market based on key parameters such as regions, products, technology, application, and end user. The projected volume and revenue growth of the global Chronic Kidney Disease market during the forecast period has also been mentioned in the report. The report further offers an insight into the prime geographical segments of the global Chronic Kidney Disease market and provides details about their past and present shares. The trends prevalent in the market have also been highlighted in the report. The study further presents an assessment of the factors that are expected to impact the growth of the market in a negative or positive way. The global Chronic Kidney Disease market has been thoroughly analyzed with regard to the respective market segments and forecast period. Each year within the respective timeline has been briefly studied in terms of the value of the product in the regional as well as global market.

Get Free PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=2288432

The healthcare sector underwent remarkable change in the last decade due to the increased use of innovative products and therapies. The evolution of dialysis technology contributes to development of the healthcare sector. Researchers focus on innovative products and machines for dialysis. Companies producing dialysis products are investing more in R&D. Home dialysis and portable dialysis machines are gaining popularity among patients suffering from end-stage kidney disease, kidney failure and acute kidney injury.

The focus of this report is the role of drugs and medical device intervention (dialysis) in the treatment and management of Chronic Kidney Disease (CKD).

The global market for CKD drugs and dialysis devices was valued at REDACTED in 2017 and is expected to witness a growth of REDACTED CAGR to reach REDACTED by 2023.

Reasons for Doing This Study

The economic impact of CKD remains a global crisis. Even with the gradual shift in treatment guidelines and innovation, nearly 10% of the U.S. population suffers from this disease that is often referred to as a silent killer. Today, one out of seven people in the U.S. have CKD. Most are unaware that they have it. Millions of patients go undiagnosed each year due to lack of treatment and affordable care. Annual treatment costs for Medicare beneficiaries with CKD are as high as $64 billion, with an additional $34 billion spent on treating patients with end stage renal disease (ESRD).

Expenditures related to kidney failure consume about 10% of the total Medicare budget, accounting for treatment of less than 1% of all Medicare recipients. The imbalance between cost and clinical outcomes associated with CKD create an impenetrable health care burden.

Kidney failure is the ninth-leading cause of death in the U.S., accounting for about 47,000 fatalities in 2013. Approximately 33 million Americans currently have CKD. Another 20 million are at increased risk for developing CKD.

More than two million people, worldwide, receive treatment: dialysis or kidney transplant. Of the subset being treated for kidney failure, the majority are treated in only five countries: the U.S., Japan, Germany, Brazil and Italy. These five countries represent only 12% of the world population. Forecasts suggest that the number of cases of kidney failure will increase disproportionately in developing countries, like China and India, where the number of elderly people is increasing.

CKD is a global health problem. This report provides a regional analysis of costs and clinical outcomes related to the management of CKD around the world. Data is further segmented by CKD stage, end user and application.

This market analysis is intended to provide analytical information to optimize business strategies. The ability to execute operating plans effectively rests on a companys ability to integrate industry research and data.

Report Scope:

Five-year projections for market activity and value are provided. Treatment types and trends for acute and chronic kidney failure, pricing considerations for medications, dialysis products (dialysis machines, dialysates and dialyzers), therapies, surgical procedures, companies, industry structure and participating companies are included in the study.

Qualitative information on disease overview, epidemiology and clinical burden of CKD is covered in detail. Further, detailed description about diagnostic methods such as blood tests, medical imaging; treatment, disease management strategies like pharmacological interventions, medical device interventions such as dialysis and kidney transplantation procedures and dietary supplements are covered. Further supporting technologies such as smartphone apps, tools and emerging technologies in dialysis and kidney transplantation procedures are also covered. Special emphasis is given to new, emerging technologies for the treatment of CKD. Market specific information on global dynamics (drivers, challenges and emerging opportunities) are covered. CKD disease management involves tedious labor, safety and cost analyses, knowledge of current policies, regulations and reimbursement. Further clinical trial and patent landscape is also covered in the report. Profiles and the overall competitive landscape of companies/manufacturers engaged in offering drugs and medical equipment for treating CKD is covered in the report.

Quantitative market size and forecast information is covered broadly by treatment, user settings and region. By treatment, the market is categorized into drugs (treatment of complications associated due to CKD, drugs for dialyzed patient groups, post-kidney transplantation procedures are covered) and medical equipment (dialysis-hemodialysis, peritoneal dialysis, kidney transplantation procedure surgical equipment). By user settings the CKD market is categorized into hospitals, specialty clinics and homecare. By region the market is categorized into North America, Europe, Asia-Pacific and RoW (Latin America, Middle East and Africa).

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=2288432

Report Includes:

- 37 data tables and 22 additional tables
- A detailed overview of the global markets for Chronic Kidney Disease (CKD)
- Analyses of global market trends with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Information on current state of chronic kidney disease, with an emphasis on biomarkers, diagnostic methods, and mobile apps that support effective disease state management
- Key insight into research on CKD comorbidities such as Diabetes and Metabolic Disease, as well as treatment methods and diagnostics
- A look at the impact of regulatory, environmental, and legislative issues on the global CKD market
- Profiles of major market players within the industry, including Abbott Laboratories, Eli Lilly and Co., Eisai, Inc., Merck & Co. and Sanofi-Aventis

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Friday, 12 May 2017

Overview of Chronic Kidney Disease : Pipeline Review, Demands, Insights, Research and Forecast 2017

ResearchMoz presents professional and in-depth study of "Chronic Kidney Disease - Pipeline Review, H1 2017".

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2017, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 18, 1, 20 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=1068460

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1068460

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://mymarketresearchlifereports.blogspot.in/